NDA 213895 · Hikma
Vancomycin
Vancomycin · Intravenous, Oral
Priority reviewDiscontinuedLast checked: Nov 20, 2026Latest source record: Aug 26, 2021 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2021
Aug 26, 2021
Approved uses
1
Original approval plus efficacy supplements
Registered trials
501
123 Phase 3, 64 recruiting
FAERS reports
65,564
60,431 serious, 12,910 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Aug 26, 2021 Original approval · Type 5 - New Formulation or New Manufacturer · priority review LetterLabelReview
1 products under this application
- VANCOMYCIN · VANCOMYCIN 5GM/100ML (50MG/ML) · SOLUTION, INTRAVENOUS, ORAL · Discontinued
Clinical trials
Interventional ClinicalTrials.gov studies with "Vancomycin" as an intervention, any sponsor and status, largest first.
- Prevention of Infections in Cardiac Surgery (PICS): a Cluster-randomized Factorial Cross-over TrialPivotal-lookingNot yet recruiting
Hamilton Health Sciences CorporationAcademic, hospital or other
NCT06567808 · 38,000 participants (planned) · Start Mar 1, 2026 · Primary completion Apr 30, 2028
Drug: Cefazolin; Vancomycin · For: Infection, Surgical Site
VA Office of Research and DevelopmentFederal agency
NCT02216227 · 23,005 participants · Start Apr 1, 2014 · Primary completion Feb 28, 2021
Drug: Mupirocin; Chlorhexidine gluconate and 3 more · For: Surgical Site Infection
Sites: Miami, Florida; Iowa City, Iowa; Baltimore, Maryland · 11 sites in all
- Infection Prophylaxis in Total Joint ReplacementPivotal-lookingRecruiting
Hamilton Health Sciences CorporationAcademic, hospital or other
NCT06126614 · 21,006 participants (planned) · Start May 7, 2024 · Primary completion Nov 2028
Drug: Chlorhexidine Gluconate; Vancomycin Hydrochloride · For: Periprosthetic Joint Infection
Sites: Hamilton, Canada
- Prevention of Arrhythmia Device Infection Trial (PADIT)Pivotal-lookingCompleted
Population Health Research InstituteAcademic, hospital or other
NCT01628666 · 12,814 participants · Start Dec 2012 · Primary completion Sep 8, 2017
Drug: Incremental; Conventional · For: Arrhythmia
Sites: Hamilton, Canada
- Staphylococcus Aureus Network Adaptive Platform TrialPivotal-lookingRecruiting
University of MelbourneAcademic, hospital or other
NCT05137119 · 8,000 participants (planned) · Start Feb 16, 2022 · Primary completion Dec 1, 2028
Drug: Cefazolin; Penicillin and 2 more · For: Staphylococcus Aureus Bacteremia
Sites: Houston, Texas; Garran, Australia; Blacktown, Australia · 161 sites in all
- Prevention of Infections in Cardiac SurgeryPivotal-lookingTerminated
Hamilton Health Sciences CorporationAcademic, hospital or other
NCT02285140 · 5,989 participants · Start Apr 2015 · Primary completion Mar 10, 2025
Drug: Cefazolin; Vancomycin · For: Thoracic Surgery; Antibiotic Prophylaxis
Sites: Hamilton, Canada; Toronto, Canada; Montreal, Canada · 4 sites in all
- Prevention of Infections in Cardiac Surgery (PICS) Prevena StudyPivotal-lookingCompleted
Population Health Research InstituteAcademic, hospital or other
NCT03402945 · 4,107 participants · Start Mar 5, 2018 · Primary completion Apr 27, 2023
Drug: Cefazolin; Vancomycin · For: Surgical Site Infections
Sites: Hamilton, Canada; London, Canada
- Simplified Selective Digestive Tract Decontamination for the Prevention of Intensive Care Unit Acquired InfectionsPivotal-lookingStatus unknown
Rambam Health Care CampusAcademic, hospital or other
NCT01798537 · 2,400 participants (planned) · Start Jun 2013 · Primary completion Jul 2015
Drug: Neomycin Colistin Nystatin Vancomycin · For: Bacteremia Associated With Intravascular Line; Ventilator Associated Pneumonia; Bacteremia
Sites: Haifa, Israel
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective7,429
- acute kidney injury4,911
- off label use4,760
- pyrexia4,067
- drug reaction with eosinophilia and systemic symptoms2,707
- renal failure2,435
- diarrhoea2,373
- sepsis2,360
- condition aggravated2,220
- pneumonia2,210
- rash2,186
- hypotension2,167
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 859 |
| 2005 | 914 |
| 2006 | 1,010 |
| 2007 | 870 |
| 2008 | 1,115 |
| 2009 | 1,029 |
| 2010 | 1,332 |
| 2011 | 1,905 |
| 2012 | 1,897 |
| 2013 | 1,859 |
| 2014 | 1,939 |
| 2015 | 2,457 |
| 2016 | 2,759 |
| 2017 | 3,352 |
| 2018 | 4,563 |
| 2019 | 4,401 |
| 2020 | 5,226 |
| 2021 | 5,112 |
| 2022 | 4,843 |
| 2023 | 4,912 |
| 2024 | 5,153 |
| 2025 | 4,995 |
| 2026 | 3,057 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Vancomycin (Vancomycin HCl In 5 % Dextrose)
2024 spending
$25K
Beneficiaries
164
462 claims
Per beneficiary
$150
$0.09 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $91,490 |
| 2021 | $76,407 |
| 2022 | $38,571 |
| 2023 | $30,391 |
| 2024 | $24,582 |
Part B: Vancomycin* (Vancomycin HCL In 5 % Dextrose*) · HCPCS J3370
2024 spending
$159K
Beneficiaries
5,120
16,321 claims
Per beneficiary
$31
2024 ASP limit $2.26 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $1,208,310 |
| 2021 | $413,086 |
| 2022 | $269,586 |
| 2023 | $189,445 |
| 2024 | $159,482 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Fidaxomicin versus vancomycin for Clostridium difficile infection.
Louie TJ, Miller MA, Mullane KM, et al. · N Engl J Med 2011 · Clinical Trial, Phase III, Comparative Study
- Epidemiology and outcomes of vancomycin-resistant enterococcus infections: a systematic review and meta-analysis.
Eichel VM, Last K, Brühwasser C, et al. · J Hosp Infect 2023 · Meta-Analysis, Systematic Review
- Risk factors for vancomycin-associated acute kidney injury: A systematic review and meta-analysis.
Kim JY, Yee J, Yoon HY, et al. · Br J Clin Pharmacol 2022 · Meta-Analysis, Systematic Review
- Vancomycin area under the curve versus trough only guided dosing and the risk of acute kidney injury: Systematic review and meta-analysis.
Abdelmessih E, Patel N, Vekaria J, et al. · Pharmacotherapy 2022 · Meta-Analysis, Research Support, N.I.H., Extramural
- Comparative effectiveness of daptomycin versus vancomycin among patients with methicillin-resistant Staphylococcus aureus (MRSA) bloodstream infections: A systematic literature review and meta-analysis.
Adamu Y, Puig-Asensio M, Dabo B, et al. · PLoS One 2024 · Comparative Study, Meta-Analysis
- Fecal Microbiota Transplantation Versus Vancomycin for Primary Clostridioides difficile Infection : A Randomized Controlled Trial.
Juul FE, Bretthauer M, Johnsen PH, et al. · Ann Intern Med 2025 · Equivalence Trial, Multicenter Study
Sponsor: Hikma
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.